Spots Global Cancer Trial Database for Empa PASS on Urinary Tract Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Empa PASS on Urinary Tract Malignancies
Official Title: Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study
Study ID: NCT03464045
Conditions
Study Description
Brief Summary: The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor and to patients initiating other Sodium glucose co-transporter-2 (SGLT-2) inhibitors (i.e. two comparator groups)
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The National Register Data, Helsinki, , Finland
The Swedish prescribed drug register, Stockholm, , Sweden
United Kingdom Clinical Practice Research Datalink (CPRD), London, , United Kingdom
Contact Details
Name: Pasi Korhonen, 358-50-3652990
Affiliation: pasi.korhonen@epidresearch.com
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
